World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
82
Citations
30512
World Ranking
3639
National Ranking
1815

Medicine

D-Index
85
Citations
33719
World Ranking
14438
National Ranking
7303

Mark M. Awad publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Mark M. Awad sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 365 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Mark M. Awad D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Mark M. Awad sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 82 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Mark M. Awad is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a particular focus on oncology and pulmonary and respiratory medicine. Their research spans multiple interconnected subfields including molecular biology, cancer research, and surgery.

The scientist's main topics of research cover several key areas:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Peptidase Inhibition and Analysis

Mark M. Awad has collaborated frequently with other researchers, including Biagio Ricciuti, Joao V. Alessi, Lynette M. Sholl, Federica Pecci, and Giuseppe Lamberti.

Their published work frequently appears in well-known venues related to oncology and cancer research, such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • JCO Precision Oncology

Among recent publications, some notable papers include:

  • "Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study" (2020, Journal of Clinical Oncology)
  • "A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer" (2020, Cell)
  • "Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial" (2020, The Lancet Oncology)
  • "Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway" (2020, Cancer Cell)
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020, Nature Medicine)

The research portfolio demonstrates a focus on lung cancer therapies and immunotherapies, often integrating clinical trials and molecular investigations. This work contributes to advancing therapies in extensive-stage small-cell lung cancer, non-small-cell lung cancer, and other cancer types such as melanoma and bladder cancer.

Best Publications

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Luc Friboulet;Nanxin Li;Ryohei Katayama;Christian C. Lee

  • Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

    Matthew D. Hellmann;Margaret K. Callahan;Mark M. Awad;Emiliano Calvo

  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer

    Adam S. Crystal;Alice T. Shaw;Lecia V. Sequist;Luc Friboulet

  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

    Patrick A. Ott;Siwen Hu-Lieskovan;Bartosz Chmielowski;Ramaswamy Govindan

  • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

    Mark Magdi Awad;Geoffrey Raymond Oxnard;David M Jackman;Daniel O. Savukoski

  • STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Amir R. Aref

  • ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)

    Paul W. Sperduto;T. Jonathan Yang;Kathryn Beal;Hubert Pan

  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

    Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

    Catherine A Shu;Justin F Gainor;Mark M Awad;Codruta Chiuzan

  • Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Natalie I. Vokes;Natalie I. Vokes;David Liu;David Liu

  • PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

    Mizuki Nishino;Nikhil H. Ramaiya;Mark M. Awad;Lynette M. Sholl

  • Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    Mark M. Awad;Ryohei Katayama;Michele McTigue;Wei Liu

  • False positive plasma genotyping due to clonal hematopoiesis

    Yuebi Hu;Bryan C. Ulrich;Julianna Supplee;Yanan Kuang

  • Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

    Guillermo De Velasco;Youjin Je;Dominick Bossé;Mark M. Awad

  • Acquired Resistance to KRASG12C Inhibition in Cancer

    Mark M Awad;Shengwu Liu;Igor I Rybkin;Kathryn C Arbour

  • Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

    Kari J. Kurppa;Yao Liu;Ciric To;Tinghu Zhang

Frequent Co-Authors

Lynette M. Sholl
Lynette M. Sholl Brigham and Women's Hospital
Mizuki Nishino
Mizuki Nishino Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Justin F. Gainor
Justin F. Gainor Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
F. Stephen Hodi
F. Stephen Hodi Harvard University
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Scott J. Rodig
Scott J. Rodig Harvard University
Andrew D. Cherniack
Andrew D. Cherniack Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees is a flexible way to expand your career options in biology and biochemistry. Many students interested in health sciences look into allied fields that complement their core studies. For example, those who want to combine life sciences with movement and wellness often pursue an online bachelor's in kinesiology, which opens doors in sports medicine, physical therapy, and fitness coaching.

For professionals aiming to advance quickly, options like the 1 year pmhnp program can prepare registered nurses for specialized roles in mental health. Similarly, the fastest post master's fnp certificate helps nurse practitioners transition efficiently into family primary care roles, which remain in high demand across the US.

Another popular pathway is nutrition science. An online dietetics programs offer affordable and convenient options for those passionate about food science, wellness, and public health. Each of these pathways helps biology and biochemistry graduates tailor their qualifications to diverse healthcare and science careers with real impact.

Best Scientists Citing Mark M. Awad

Trending Scientists

Recently Published Articles